AI news impact · US stocks

Iovance Biotherapeutics Inc (IOVA) news impact

On 2026-10-02 Wave Radar's AI rated the news on Iovance Biotherapeutics Inc as major positive (impact score +95%).

Iovance significantly raised its 2026 revenue outlook, projecting up to 60% growth driven by strong demand for its cancer therapies, causing shares to surge over 31% to a 52-week high.

Direction
Major positive
Impact score
+95%
Confidence
95%
Headlines read
5
Date
2026-10-02
Open IOVA news in Wave Radar

AI assessment

Iovance significantly raised its 2026 revenue outlook, projecting up to 60% growth driven by strong demand for its cancer therapies, causing shares to surge over 31% to a 52-week high.

Sector impact

Provides a strong positive signal for the cell therapy and innovative cancer treatment sector.

Headlines the AI read

Rating history

One rating per trading day the stock was covered.

More on Iovance Biotherapeutics Inc

IOVA valuation · IOVA gamma exposure

How the rating works

After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.